4-(溴甲基)苯基氨基甲酸叔丁酯 | 239074-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(溴甲基)苯基氨基甲酸叔丁酯
• 中文别名: N-BOC-4-(溴甲基)苯胺；N-[4-(溴甲基)苯基]氨基甲酸叔丁酯
• 英文名称: tert-butyl (4-(bromomethyl)phenyl)carbamate
• 英文别名: tert-butyl N-[4-(bromomethyl)phenyl]carbamate
• CAS: 239074-27-2
• 化学式: C₁₂H₁₆BrNO₂
• 分子量: 286.169
• InChiKey: UOFFCPRGVVQWTL-UHFFFAOYSA-N

物化性质

• 沸点：
  309.7±25.0 °C(Predicted)
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P280,P305+P351+P338,P310
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-(bromomethyl)phenylcarbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-(bromomethyl)phenylcarbamate
CAS number: 239074-27-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H16BrNO2
Molecular weight: 286.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)苯基氨基甲酸叔丁酯 在 盐酸 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  用于四嗪触发的细胞内醇释放的自消灭性接头的开发。

  摘要：

  生物正交降解反应是前药活化的一种有前途的策略，因为它们涉及键断裂以释放目标分子。反式-环辛烯（TCO）-四嗪逆电子需求的Diels-Alder反应已在体内广泛用于降低胺前药的含量，但是，对含醇生物活性化合物的释放研究较少。在这里，我们报告了与四嗪触发器反应后释放OH分子的TCO-氨基甲酸酯苄基醚自消灭性连接体。苄基醚连接物被证明是高度稳定的，并且在与四嗪类反应后可以在生理条件下迅速释放出醇。使用荧光TCO-苄基醚-香豆素探针和不同的3种化合物，通过荧光和HPLC分析系统地检查了机理和降解率。6-取代的四嗪衍生物。这项研究表明，降级迅速发生（t1 / 2 = 27分钟），环加成步骤在几秒钟内（t1 / 2 = 7 s）发生，反应速率约为100 M-1 s-1。重要的是，该反应与活生物体相容，如在活大肠杆菌存在下抗菌化合物三氯生前药的降解证明的那样，该反应通过释放的“ OH-活性药物”的作用导

  DOI：

  10.1039/c9ob01167f
• 作为产物：
  描述：

  对氨基苯甲醇 在 三溴化磷 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 40.0h， 生成 4-(溴甲基)苯基氨基甲酸叔丁酯
  参考文献：
  名称：

  用于四嗪触发的细胞内醇释放的自消灭性接头的开发。

  摘要：

  生物正交降解反应是前药活化的一种有前途的策略，因为它们涉及键断裂以释放目标分子。反式-环辛烯（TCO）-四嗪逆电子需求的Diels-Alder反应已在体内广泛用于降低胺前药的含量，但是，对含醇生物活性化合物的释放研究较少。在这里，我们报告了与四嗪触发器反应后释放OH分子的TCO-氨基甲酸酯苄基醚自消灭性连接体。苄基醚连接物被证明是高度稳定的，并且在与四嗪类反应后可以在生理条件下迅速释放出醇。使用荧光TCO-苄基醚-香豆素探针和不同的3种化合物，通过荧光和HPLC分析系统地检查了机理和降解率。6-取代的四嗪衍生物。这项研究表明，降级迅速发生（t1 / 2 = 27分钟），环加成步骤在几秒钟内（t1 / 2 = 7 s）发生，反应速率约为100 M-1 s-1。重要的是，该反应与活生物体相容，如在活大肠杆菌存在下抗菌化合物三氯生前药的降解证明的那样，该反应通过释放的“ OH-活性药物”的作用导

  DOI：

  10.1039/c9ob01167f

文献信息

• [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2021003295A1

  公开（公告）日：2021-01-07

  The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。
• Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs
  作者：Claudia Karnthaler-Benbakka、Diana Groza、Bettina Koblmüller、Alessio Terenzi、Katharina Holste、Melanie Haider、Dina Baier、Walter Berger、Petra Heffeter、Christian R. Kowol、Bernhard K. Keppler

  DOI：10.1002/cmdc.201600417

  日期：2016.11.7

  Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2‐nitroimidazole‐based hypoxia‐activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli

  酪氨酸激酶抑制剂 (TKI) 在过去 15 年中彻底改变了癌症治疗，但由于严重的副作用，其临床应用受到限制。因此，我们将两种获批的 TKI（舒尼替尼和厄洛替尼）转化为基于 2-硝基咪唑的缺氧可激活前药。动力学研究显示 24 小时内的稳定性差异很大；然而，通过大肠杆菌快速还原激活可以确认两个面板的硝基还原酶。在细胞培养中评估了化合物对各种人类癌细胞系的抗癌活性和信号抑制作用。这些数据，连同分子对接模拟，揭示了结构修饰对药物与酶结合的影响的明显差异：而表皮生长因子受体 (EGFR) 的催化口袋接受所有新的厄洛替尼衍生物，即血管内皮生长因子受体舒尼替尼前药的 (VEGFR) 抑制潜力因衍生化而显着降低。与此一致，使用舒尼替尼前药观察到 ERK 信号抑制的缺氧依赖性，而氧水平对厄洛替尼衍生物的活性没有影响。全面的，
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• [EN] FLAVONOID DIMERS AND THEIR USE<br/>[FR] DIMÈRES FLAVONOÏDES ET LEURS APPLICATIONS
  申请人：UNIV MCGILL

  公开号：WO2011137516A1

  公开（公告）日：2011-11-10

  This invention relates to bis-flavonoid compounds of formula Flavonoid-Linker-Y-Linker-Flavonoid, their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.

  这项发明涉及到公式为黄酮素-连接子-Y-连接子-黄酮素的双黄酮类化合物，它们的合成以及在化疗和原虫感染中抑制多药耐药性的用途。
• [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044770A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  具有式（IX）的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义，并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病，包括癌症的方法。